kuppi
2021-12-17
Very difficult to digest what is happening in the market.
Not a good sign for investors
After-Hours Stock Movers: Spruce Biosciences,Rivian,FedEx,General Motors and more
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":690576543,"tweetId":"690576543","gmtCreate":1639697899985,"gmtModify":1639697900620,"author":{"id":3575011341539105,"authorId":3575011341539105,"authorIdStr":"3575011341539105","name":"kuppi","avatar":"https://static.tigerbbs.com/1a1c96e4fc6f6f67de0450751c853214","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":68,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Very difficult to digest what is happening in the market.</p><p>Not a good sign for investors</p></body></html>","htmlText":"<html><head></head><body><p>Very difficult to digest what is happening in the market.</p><p>Not a good sign for investors</p></body></html>","text":"Very difficult to digest what is happening in the market. Not a good sign for investors","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/690576543","repostId":2192942001,"repostType":4,"repost":{"id":"2192942001","pubTimestamp":1639697332,"share":"https://www.laohu8.com/m/news/2192942001?lang=&edition=full","pubTime":"2021-12-17 07:28","market":"us","language":"en","title":"After-Hours Stock Movers: Spruce Biosciences,Rivian,FedEx,General Motors and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2192942001","media":"StreetInsider","summary":"After-Hours Stock Movers:\nSpruce Biosciences, Inc. (NASDAQ: SPRB) 26.6% HIGHER; Oppenheimer initiate","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/SPRB\">Spruce Biosciences, Inc.</a> (NASDAQ: SPRB) 26.6% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $15.00.</p>\n<p>Eloxx Pharma (NASDAQ: ELOX) 7.7% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $4.00.</p>\n<p>Rivian Automotive (NASDAQ: RIVN) 10.2% LOWER; reported Q3 EPS of ($12.21), versus ($2.88) reported last year. Announces 71K net preorders for R1 in U.S. and Canada. Sees planned ~200K annual capacity at Normal, IL, and estimated 400K annual capacity at Georgia facility.</p>\n<p>Steelcase (NYSE: SCS) 6.2% LOWER; reported Q3 EPS of $0.08, $0.01 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $738.2 million versus the consensus estimate of $767.62 million. Steelcase sees Q4 2022 EPS of $0.00, versus the consensus of $0.12. Steelcase sees Q4 2022 revenue of $740-765 million, versus the consensus of $770.77 million.</p>\n<p>FedEx (NYSE: FDX) 4.8% HIGHER; reported Q2 EPS of $4.83, $0.56 better than the analyst estimate of $4.27. Revenue for the quarter came in at $23.5 billion versus the consensus estimate of $22.44 billion. FedEx (NYSE: FDX) sees FY 2022 EPS of $20.50 to $21.50, versus the consensus of $19.64.</p>\n<p><a href=\"https://laohu8.com/S/FOUR\">Shift4 Payments, Inc.</a> (NYSE: FOUR) 3.8% HIGHER; authorized the commencement of a stock repurchase program. The stock repurchase program authorizes the Company to repurchase up to $100 million of the Companys Class A common stock, par value $0.0001 (Common Stock) and will expire on December 31, 2022, subject to market conditions, contractual restrictions and other factors.</p>\n<p>General Motors Company (NYSE: GM) 2.9% LOWER; Dan Ammann, the CEO of the self-driving division Cruise, is leaving the company, with Kyle Vogt, the President and CTO of Cruise to serve as an interim CEO.</p>\n<p>United States Steel Corporation (NYSE: X) 5.3% LOWER; provided fourth quarter 2021 guidance. Fourth quarter 2021 adjusted EBITDA is expected to be approximately $1.65 billion.</p>\n<p>Biomea Fusion Inc. (NASDAQ: BMEA) 2.8% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $22.00.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Spruce Biosciences,Rivian,FedEx,General Motors and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Spruce Biosciences,Rivian,FedEx,General Motors and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 07:28 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=19364278><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nSpruce Biosciences, Inc. (NASDAQ: SPRB) 26.6% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $15.00.\nEloxx Pharma (NASDAQ: ELOX) 7.7% ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19364278\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OWL":"Blue Owl Capital Inc.","FDX":"联邦快递","X":"美国钢铁","GM":"通用汽车","SCS":"Steelcase Inc.","FOUR":"Shift4 Payments, Inc.","ELOX":"Eloxx制药","BK4139":"生物科技","SPRB":"Spruce Biosciences, Inc.","BK4516":"特朗普概念","RIVN":"Rivian Automotive, Inc.","BK4007":"制药","BK4211":"区域性银行","BK4099":"汽车制造商","BK4135":"资产管理与托管银行"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19364278","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192942001","content_text":"After-Hours Stock Movers:\nSpruce Biosciences, Inc. (NASDAQ: SPRB) 26.6% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $15.00.\nEloxx Pharma (NASDAQ: ELOX) 7.7% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $4.00.\nRivian Automotive (NASDAQ: RIVN) 10.2% LOWER; reported Q3 EPS of ($12.21), versus ($2.88) reported last year. Announces 71K net preorders for R1 in U.S. and Canada. Sees planned ~200K annual capacity at Normal, IL, and estimated 400K annual capacity at Georgia facility.\nSteelcase (NYSE: SCS) 6.2% LOWER; reported Q3 EPS of $0.08, $0.01 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $738.2 million versus the consensus estimate of $767.62 million. Steelcase sees Q4 2022 EPS of $0.00, versus the consensus of $0.12. Steelcase sees Q4 2022 revenue of $740-765 million, versus the consensus of $770.77 million.\nFedEx (NYSE: FDX) 4.8% HIGHER; reported Q2 EPS of $4.83, $0.56 better than the analyst estimate of $4.27. Revenue for the quarter came in at $23.5 billion versus the consensus estimate of $22.44 billion. FedEx (NYSE: FDX) sees FY 2022 EPS of $20.50 to $21.50, versus the consensus of $19.64.\nShift4 Payments, Inc. (NYSE: FOUR) 3.8% HIGHER; authorized the commencement of a stock repurchase program. The stock repurchase program authorizes the Company to repurchase up to $100 million of the Companys Class A common stock, par value $0.0001 (Common Stock) and will expire on December 31, 2022, subject to market conditions, contractual restrictions and other factors.\nGeneral Motors Company (NYSE: GM) 2.9% LOWER; Dan Ammann, the CEO of the self-driving division Cruise, is leaving the company, with Kyle Vogt, the President and CTO of Cruise to serve as an interim CEO.\nUnited States Steel Corporation (NYSE: X) 5.3% LOWER; provided fourth quarter 2021 guidance. Fourth quarter 2021 adjusted EBITDA is expected to be approximately $1.65 billion.\nBiomea Fusion Inc. (NASDAQ: BMEA) 2.8% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $22.00.","news_type":1},"isVote":1,"tweetType":1,"viewCount":296,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":72,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/690576543"}
精彩评论